Web Results


Judgment of the Court (First Chamber) of 7 July 2016. Genentech Inc. v Hoechst GmbH and Sanofi-Aventis Deutschland GmbH. Request for a preliminary ruling from the Cour d'appel de Paris. Reference for a preliminary ruling — Competition — Article 101 TFEU — Non-exclusive licence agreement — Patent — No ...


May 10, 2013 ... Case opinion for US Federal Circuit SANOFI AVENTIS DEUTSCHLAND GMBH v. Biogen Idec Inc., Defendant.. Read the Court's full decision on FindLaw.


Jan 12, 2016 ... Teriflunomide is the active metabolite of leflunomide (ARAVA®, Sanofi-Aventis Deutschland GmbH, Germany), a disease-modifying antirheumatic drug ... endpoint) by 31.5 % (p < 0.001) and reduced the risk of disability progression ( key secondary endpoint) by 30.0 % (p < 0.05) versus placebo (Table 2).